Copyright
©The Author(s) 2025. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Surg. Mar 27, 2025; 17(3): 103740
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.103740
Published online Mar 27, 2025. doi: 10.4240/wjgs.v17.i3.103740
Neoadjuvant therapy: Dawn of reducing the high post-surgery recurrence rate of hepatocellular carcinoma
Xiao-Dong Zhang, Jia-Liang Luo, Ke-Heng Yu, Ke-Lei Zhu, Department of Hepatopancreatobiliary Surgery, The Affiliated People's Hospital of Ningbo University, Ningbo 315040, Zhejiang Province, China
Lu-Yi Zhang, Zhejiang Provincial Key Laboratory of Pathophysiology, Health Science Center, Ningbo University, Ningbo 315211, Zhejiang Province, China
Author contributions: Zhang XD performed the majority of the writing, performed data accusation; Zhang LY prepared the figures and tables; Luo JL and Yu KH provided the input in writing the paper; Zhu KL designed the outline and coordinated the writing of the paper.
Supported by the Zhejiang Provincial Medical and Health Science and Technology Plan, No. 2022ZH050; and the Health Science and Technology Project of Yinzhou District, No. 2023Y03.
Conflict-of-interest statement: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as potential conflicts of interest.
Open Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Ke-Lei Zhu, Chief Physician, MD, PhD, Department of Hepatopan
Received: December 3, 2024
Revised: January 1, 2025
Accepted: January 14, 2025
Published online: March 27, 2025
Processing time: 87 Days and 0.2 Hours
Revised: January 1, 2025
Accepted: January 14, 2025
Published online: March 27, 2025
Processing time: 87 Days and 0.2 Hours
Core Tip
Core Tip: Currently, numerous articles focus on preoperative antitumor therapy for hepatocellular carcinoma (HCC). Of note, this review uniquely examines neoadjuvant therapy for HCC within the context of combination therapy from the perspective of the China Liver Cancer Stage. Drawing on the Chinese guidelines, it addresses the definition of the neoadjuvant therapy concept, identifies the target population, evaluates the outcomes of various treatment strategies, and discusses the challenges regarding neoadjuvant therapy for HCC.